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Available online 11 July 2017Diabetic retinopathy (DR) is a complication secondary to diabetes and is the number one cause of blindness
among working age individuals worldwide. Despite recent therapeutic breakthroughs using pharmacotherapy,
a cure for DR has yet to be realized. Several clinical trials have highlighted the vital role dyslipidemia plays in
the progression of DR. Additionally, it has recently been shown that activation of Liver X receptor (LXRα/
LXRβ) prevents DR in diabetic animalmodels. LXRs are nuclear receptors that play key roles in regulating choles-
terol metabolism, fatty acid metabolism and inﬂammation. In this manuscript, we show insight into DR patho-
genesis by demonstrating an innovative signaling axis that uniﬁes key metabolic regulators, Sirtuin 1 and LXR,
inmodulating retinal cholesterol metabolism and inﬂammation in the diabetic retina. Expression of both regula-
tors, Sirtuin 1 and LXR, are signiﬁcantly decreased in diabetic human retinal samples and in a type 2 diabetic an-
imal model. Additionally, activation of LXR restores reverse cholesterol transport, prevents inﬂammation,
reduces pro-inﬂammatory macrophages activity and prevents the formation of diabetes-induced acellular capil-
laries. Taken together, the work presented in this manuscript highlights the important role lipid dysregulation
plays in DR progression and offers a novel potential therapeutic target for the treatment of DR.versity, 5
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Diabetic retinopathy (DR) is the number one cause of blindness
among working age adults. Despite recent advances using pharmaco-
therapy, a cure for DR has yet to be realized. The recent evidence from
large clinical trials demonstrating a strong association between lipid ab-
normalities and DR progression provides a unique opportunity to un-
cover innovative pathogenic mechanisms in DR (Ferris et al., 1996;
Lyons et al., 2004; Keech et al., 2005). Speciﬁcally, recent studies dem-
onstrate that intensive control of cholesterol levels can signiﬁcantly
slow down DR progression in type 2 diabetic individuals (Keech et al.,
2005; Klein et al., 1999; Du et al., 2013). Unlike macrovascular67 Wilson Rd, Biomed
f Medicine, R3-C426D,
du (M.B. Grant).
an open access article undercomplications, theDiabetes Control and Complications Trial (DCCT), Ep-
idemiology of Diabetes Interventions and Complications (EDIC) and the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye trials,
as well as Blue Mountain Eye Study and the Wisconsin Epidemiologic
Study of Diabetic Retinopathy (WESDR) studies did notﬁnda direct cor-
relation between the development of DR and circulating lipid levels,
suggesting that retinal-speciﬁc mechanisms may be at play.
We have previously demonstrated that diabetic dyslipidemia pro-
motes retinal vascular degeneration at several levels. First, changes in
retinal-speciﬁc lipid metabolism can contribute to low-grade chronic
inﬂammation resulting in endothelial cell injury (Opreanu et al.,
2011). Second, there is inadequate repair of the injured retinal capil-
laries by bone marrow-derived (BMD) circulating angiogenic cells
(CACs) (Chakravarthy et al., 2016). These cells are exquisitely sensitive
to the damaging diabeticmilieu and are adversely impacted by dyslipid-
emia. Finally, activatedmyeloid cells promote a pro-inﬂammatory envi-
ronment in the retina (Chakravarthy et al., 2016; Hazra et al., 2013).
Thus, retinal endothelial cell injury, activated myeloid cells and failedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in progression to the vaso-degenerative stage of the disease. The role
of diabetes-induced cholesterol metabolic abnormalities at each of
these levels is addressed in this study.
Cholesterol metabolism of retina and brain is unique among periph-
eral organs due to the tight barrier separating them from systemic circu-
lation (Dietschy and Turley, 2001; Fliesler and Bretillon, 2010). In the
brain, cholesterol is exclusively supplied by local synthesis. Retina also
synthesizes cholesterol, but unlike brain, retina has mechanisms for
cholesterol delivery from the systemic circulation (Fliesler et al., 1993;
Pikuleva and Curcio, 2014; Tserentsoodol et al., 2006). In healthy retina,
most of the blood-borne cholesterol is delivered via the outer blood ret-
inal barrier (BRB) located at the RPE layer (Fliesler and Bretillon, 2010).
In the diabetic retina, an abnormal increase in cholesterol uptake is ob-
served in the inner BRB (retinal microvasculature) in addition to the
outer BRB (Fliesler et al., 1993; Zheng et al., 2012). Retinal vasculature
and RPE play an important role in cholesterol elimination. Unlike most
peripheral tissues where HDL-mediated reverse cholesterol transport
(RCT) represents the major pathway of cholesterol elimination, both
RCT and metabolism of cholesterol to more soluble oxysterols, are
active in the retina (Mast et al., 2011; Pikuleva and Curcio, 2014;
Tserentsoodol et al., 2006). Theﬁrst step of RCT, cellular efﬂux of choles-
terol, is controlled by ATP binding cassette transporters ABCA1 and
ABCG1, scavenger receptor class B type I (SR-BI), cluster of differentia-
tion 36 (CD36), and caveolin-1, all expressed in the retina (Duncan
et al., 2009; Tserentsoodol et al., 2006). The second elimination path-
way, metabolism of cholesterol to more soluble oxysterols, is realized
via cytochromeP450 enzymes (CYPs). The oxysterol proﬁle of the retina
suggests that all known pathways of cholesterol metabolism in
extraocular organs are operative in the retina.
Oxysterols serve as endogenous ligands of liver X receptors (LXRα
(NR1H3)/LXRβ (NR1H2)) (Janowski et al., 1996). In addition to their
established role in cholesterol metabolism (Janowski et al., 1999),
LXRs also suppress inﬂammatory gene expression, thus controlling im-
mune response and inﬂammation (Huang et al., 2011; Ogawa et al.,
2004; Pascual et al., 2005). Importantly, LXR null mice, even in the ab-
sence of hyperglycemia, present with pathological changes seen in the
diabetic retina, dramatically reduced CAC function and increased levels
of activated macrophages (Hazra et al., 2012). Another key metabolic
regulator, Sirtuin 1 (SIRT1), was recently shown to exert its beneﬁcial
effect through LXR-dependent mechanisms (Li et al., 2007). SIRT1 is
the mammalian ortholog of yeast Sir2 gene that has been shown to
play a role in aging, apoptosis, neural protection, glucose metabolism
and neural development (Miranda et al., 2015; Purushotham et al.,
2009; Wang et al., 2011). SIRT1 interacts with LXR to promote its
deacetylation at a single conserved lysine (K432 in LXRα and K433 in
LXRβ) adjacent to the ligand-regulated activation domain, leading to
LXR activation (Li et al., 2007). Via LXR activation, SIRT1 promotes insu-
lin secretion, reduces glucose tolerance and decreases body weight
(Zabolotny and Kim, 2007; Purushotham et al., 2009; Wang et al.,
2011). Importantly, SIRT1 is critical to vascular health (Kitada et al.,
2016). High glucose adversely inﬂuences CAC function by reducing
SIRT1, while increasing SIRT1 in CACs of diabetic origin corrects their
dysfunction (Balestrieri et al., 2008, 2013; Yuen et al., 2012). Animal
and in vitro studies have demonstrated the importance of SIRT1 regula-
tion of inﬂammation (Zabolotny and Kim, 2007; Howitz et al., 2003;
Liang et al., 2009). Activation of SIRT1, followed by LXR deacetylation
resulted in inhibition NFκB activity induced by high-fat diet, and
sustained repression of inﬂammatory genes (Zeng et al., 2013). By con-
trast, SIRT1-KOmice on a high-fat diet were prone to liver inﬂammation
(Purushotham et al., 2009). In primary macrophages, deﬁciency of
SIRT1 decreased the induction of the LXR target gene, ABCA1, impairing
cholesterol export. Activation of SIRT1 enhanced LXRα, activity and
ABCA1 and ABCG1 expression (Li et al., 2007). SIRT1-LXRα axis is also
signiﬁcantly reduced in U937 cells during foam cell formation (Zeng
et al., 2013). Finally, decreased SIRT1 levels have recently beenimplicated in the pathogenesis of microvascular complications, speciﬁ-
cally DR (Kowluru et al., 2014). The interplay of SIRT1 with LXR in the
pathogenesis of DR has not been previously investigated and represents
the focus of this study.
2. Materials and Methods
2.1. Animal Studies
All animal procedures were in compliance with the National Insti-
tutes of Health (NIH) Guide for the Care and Use of Laboratory Animals,
and with the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision Research. Dia-
betic, Leprdb/db (B6.BKS(D)-Leprdb/J) and their corresponding controls
Leprdb/m, were purchased by Jackson laboratories (Coleman, 1978).
The procedures were carried out in accordance with the guidelines of
the Indiana University School of Medicine, Institutional Animal Care
and Use Committee (IACUC). For experiments with GW3965 treatment
8-week-oldmale db/dbmicewere fed a chow dietmixedwith GW3965
at a dose of 10mg/kg bodyweight/day for 12weeks. The type 2 diabetic
BBZD rat model (4 months diabetes) was used to measure retinal cho-
lesterol metabolism (Tirabassi et al., 2004; Busik et al., 2009).
2.2. Cell Culture and Treatment
Primary cultures of human retinal endothelial cells (HRECs) were
prepared from the retinas provided by National Disease Research Inter-
change (Philadelphia, PA, USA) as previously described (Wang et al.,
2014, 2016b). Characteristics of the donors are summarized in Wang
et al. (2014). Bovine retinas were isolated from eyes donated by the
Michigan State University Meat Laboratory. BRECs were isolated and
validated according to a previously published protocol (Antonetti
et al., 1998). BREC identity was conﬁrmed morphologically and by re-
sponse to vascular endothelial growth factor (293-VE), Anti-Von
Williebrand Factor immunocytochemistry (ab6994) and LDL uptake
assay (ab133127; Abcam; Cambridge, MA) (Stewart et al., 2011).
BREC were cultured in 10% Fetal Bovine Serum (FBS) Complete Media
with 1% Antibiotic/Antimycotic (AA) (Gibco; ThermoFisher; Waltham,
MA). Passages 4–8 were used for all experiments. Prior to treatment,
cells were grown to 80% conﬂuency and serum starved overnight (12–
18 h). BREC were serum starved in 1% Fetal Bovine Serum Complete
media. Cells were treated with diabetic relevant stimuli tumor necrosis
factor alpha (TNFα) for 24 h (10 ng/ml) (2279-BT; R&D Systems)
(Wang et al., 2016a). In order to activate the SIRT1-LXR pathway,
BRECs were treated with LXR activator, DMHCA (0.1 μM/1 μM)
(700125P; Avanti Polar Lipids; Alabaster, AL), GW3965 (10 μM)
(10054; Cayman Chemical; Ann Arbor, MI) or SIRT1 activator SRT1720
(1 μg) (S1129; Sellechem; Houston, TX) for 24 h (Mitchell et al., 2014;
Kratzer et al., 2009).
2.3. Real-time Quantitative PCR
RNA from HREC and BREC was isolated according with the RNeasy
mini kit (74106; Qiagen, Valencia, CA) according to manufacturer's in-
structions. First-strand complementary DNA was synthesized from iso-
lated RNA using SuperScript II reverse transcription (18064014;
Invitrogen). Prepared cDNAwasmixedwith 2× SYBRGreen PCRMaster
Mix (4309155; Applied Biosystems) and various sets of gene-speciﬁc
forward and reverse primers (LXRα, LXRβ, ABCA1, ABCG1, IL1β, IL-6,
SIRT1 and SREBP-1c (Integrated DNA Technologies; Coralville, IA) and
subjected to real-time PCR quantiﬁcation using the ABI PRISM 7700 Se-
quence Detection System (Applied Biosystems). Primer sequences are
identiﬁed in Table 1. All reactions were performed in triplicate.
Cyclophilin A was used as a control, and results were analyzed using
the comparative Ct method and Ct values were normalized to
Cyclophilin A levels. Data is shown as normalized relative to control
Table 1
Qualitative real time PCR primer sequences.
Primer
name
Forward (5′ to 3′) Reverse (5′ to 3′)
Cyclophilin A GAG CAC TGG AGAGAAAGGATT T GAC TTG CCA GTA CCA TTA T
LXRα GAG AGG CTG CAA CAC ACA TA AGG CTC ACC AGT TCA TCA G
LXRβ GAA GGT GAA GGT GTC CAG TT GTC GGA GAA GGA GCG TTT ATT
ABCA1 CTC AGT GGG ATG GAT GGT AAA G TGG CAA TCA GCA GTC TCT TC
ABCG1 AGA CCT GCC ATT TCC AGA AG GAT GAG ACG CAG GGA GAT
AAA G
SIRT1 CCC TGA AAG TAA GAC CAG TAG C GTG AGG CAA AGG TTC CCT ATT A
IL-1β CTA TTC TCT CCA GCC AAC CTT C CTC GTC ACT GTA GTA AGC CAT C
IL-6 CCA GAA CGA GTA TGA GGG AAA
TC
TTG TGG CTG GAG TGG TTA TTA G
SREBP-1 GAC TAC ATC CGC TTC CTT CAG CCA GGT CCT TCA GCG ATT T
Table 2
Control and SIRT1-directed siRNA oligomer sequences.
Primer name Primer number Sequence (5′ to 3′)
SIRT1 314004G12 (RNA)- CAA ACU UGA AGA AUG GUC UUG GGU C
314004H01 (RNA)- GAC CCA AGA CCA UUC UUC AAG UUU G
Control 314004H02 (RNA)- GAC GAA CCA UUA UUC AAC UGC CUU G
314004H03 (RNA)- CAA GGC AGU UGA AUA AUG GUU CGU C
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enucleated and retinas were dissected. RNA from retinas and bonemar-
row derived macrophages was isolated using the RNeasy mini Kit
(Qiagen). Reverse transcription was done using the Superscript VILO
cDNA Synthesis Kit (11754050; Life Technologies). Real-time PCR was
performed on an ABI PRISM 7900HT Sequence Detection System,
using TaqMan Fast Universal PCRMasterMix (2×) (4352042; Life Tech-
nologies) and TaqMan primer/probe gene expression assays. The
expression ofβ-2microglobulin and cyclophillin-βwere used as endog-
enous controls. The relative copy number was calculated as
1/POWER(2,ΔCT)*100.
2.4. Acellular Capillaries
The sensory retinawas isolated by gently separating it from pigment
epithelium and choroid using a #00 paint brush under a dissecting mi-
croscope. Capillaries prepared using elastase digestion, and stainedwith
hematoxylin and periodic acid–Schiff as detailed in Veenstra et al., 2015
and previously described (Kern et al., 2000; Laver et al., 1993; Opreanu
et al., 2011; Veenstra et al., 2015). Acellular capillaries were quantiﬁed
in a masked, randomized manner by three independent examiners
(Laver et al., 1993; Opreanu et al., 2011; Veenstra et al., 2015).
2.5. Oxysterol Measurement
Retinal samples were subjected to total lipid extraction by a
monophasic chloroform/methanol/water mixture simultaneously ex-
tract cholesterol, oxysterols, and cholesteryl esters (Lydic et al., 2014).
Oxysterols were analyzed by LC-MS/MS on an ultra- high resolution/ac-
curatemass LTQ-Orbitrap velos platform (Thermo Scientiﬁc) coupled to
an Agilent 1260 capillary HPLC. LC gradient conditions were based on
LIPID MAPS LC-MS/MS methodology for sterol and oxyterol analysis
modiﬁed by use of a ProntoSIL C18AQ 3 μ 120 Å, 0.2 mm × 50mm cap-
illary LC column (nanoLCMS Solutions) at a ﬂow rate of 2 μl/min
(Mcdonald et al., 2007). The columnwas directly coupled to aNano-AD-
VANCE nESI source (Bruker-Michrom). Chromatographic peak align-
ment, compound identiﬁcation, and quantitation were performed
with Maven software in conjunction with an in-house database of me-
tabolite identities and retention times (Melamud et al., 2010). Choles-
terol, cholesteryl esters, and other nonpolar lipids were analyzed by
direct infusion nESI ultra high resolution/accurate mass MS and MS/
MS as previously described by us (Lydic et al., 2014).
2.6. Bone Marrow Derived Macrophages (BMDM)
Macrophages were derived from cultures of murine bone marrow
cells (2.5 × 106 cells/well, 3 ml/well) in 6-well plates with macrophage
growth media: RPMI-L929 (Sigma-Aldrich, St. Louis, MO) supplement-
ed with 10% heat inactivated donor equine serum (HyClone, GE
Healthcare Life sciences, Pittsburgh, PA), 5% heat inactivated fetal bo-
vine serum (Gibco™, Thermo Fischer), 15% L929-conditioned media,1×–L-glutamine (Gibco™) and 1× antibiotics (Gibco™). Media changes
were performed at 3, and at day 6. On Day 7, macrophages were stimu-
lated for the next 18 h with LPS (100 ng/ml, Sigma) and murine IFN-γ
(40 ng/ml, life sciences) or with metabolic stimuli consisting of
30 mM glucose (using 45% glucose solution, Gibco™), 10 nM insulin
(Humulin, R, Lilly), 400 μM palmitate (N-16-A, Nu-Chekprep, Elysian,
MN) according to (Kratz et al., 2014) 10 μM GW3965 (Sigma) was
added with the stimulation for 18 h. Control medium was RPMI –
1640 enriched with 10% heat inactivated donor equine serum, 5% FBS,
antibiotics, L-glutamine and 11.1 mM glucose. In all media, glucose
was adjusted to 11.1mMor 30mMwith the addition of 45% glucose so-
lution (Gibco™). At the end of the experiment, cellswere lysed andRNA
was extracted as described above.
2.7. siRNA Transfection
SIRT1 siRNA transfectionswere conductedusingAmaxaHumanCor-
onary Artery Endothelial Cells (HCAEC) Nucleofector Kit (V4XP-5024;
Lonza; Cologne, Germany). SIRT1 directed oligomers and control
siRNA oligomers were designed using Custom Stealth RNAi siRNA tool
(ThermoScientiﬁc). siRNA sequences are identiﬁed in Table 2. Two dif-
ferent sets of SIRT1 directed siRNA oligomers were used but SIRT1
knockdown efﬁciency was only achieved using the sequences demon-
strated in Table 2. Supplemental Fig. 1 demonstrates the SIRT1 siRNA
oligomers that were unsuccessful in blocking SIRT1 mRNA levels
in BREC.
2.8. Western Blot Analysis
BRECwere cultured and treated as necessary. Lysates were collected
by scraping cells using cold 1× radioimmunoprecipitation assay buffer
(RIPA) with protease and phosphatase inhibitor (89900; Thermo Scien-
tiﬁc). Bradford protein assay was used to measure total protein level
and equal amounts of protein (25 μg) were loaded in each well. 10%
Bis-Tris NuPAGE gels were transferred to 0.2 μm nitrocellulose mem-
branes. Membranes were probed overnight with ABCA1 (ab18180;
Abcam), and β-actin antibodies (4970; Cell signaling technology: Dan-
vers, MA). β-actin was used as a loading control. Blots were analyzed
using the LI-COR Odyssey imaging and quantiﬁcation system.
2.9. Enzyme Linked Immunosorbent Assay (Elisa)
BREC were grown in 24-well dishes until 80% conﬂuent. Cells were
treated as mentioned above (cell culure and treatment), and media
was collected for analysis. IL6 and IL1β protein levels were measured
via ELISA (IL6, ab205080, abcam; IL1β, ESS0027, Thermo Scientiﬁc)
treatment with TNFα and/or LXR activator, DMHCA. Manufactures in-
structions were followed for each kit.
2.10. Circulating Angiogenic Cell (CAC) Migration
CAC function was determined by measuring migration using the
QCM™ chemotaxis 5 μM 96-well cell migration assay (Chemicon Inter-
national, Inc.) as per themanufactures instructions. Migratory response
to stromal derived factor-1 (SDF-1) or VEGF was expressed as arbitrary
ﬂuorescence unit (AFU) (Balaiya et al., 2014).
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A Student t-test was used for comparisons between two groups. One-
way ANOVA, followed by the Tukey post hoc test, was used for multiple
comparisons. All values are expressed as mean ± SEM. A value of
p b 0.05 was considered to be statistically signiﬁcant. Statistical
tests were performed using statistics software (GraphPad Software;
La Jolla, CA).
3. Results
3.1. Diabetes Leads to Signiﬁcant Decrease in LXRα, LXRβ and SIRT1 Levels
in Retina and Retinal Cells
To determine the effect of diabetes on SIRT1-LXR axis, retinas from
Leprdb/db 10-month diabetic mice were isolated and LXRα and SIRT1
mRNA expression levels were compared to their corresponding Leprdb/m
controls. TNFα expression was used to conﬁrm increased inﬂammatory
cytokine expression in diabetic retina (Fig. 1a). As shown in Fig. 1a, diabet-
ic retinas had signiﬁcantly decreased LXRα expression level as compared
to control. We next determined LXR and SIRT1 expression levels in
human retinal endothelial cells (HRECs) isolated from previously charac-
terized (Wang et al., 2016b) diabetic human donor tissue with conﬁrmed
dyslipidemia and upregulation of pro-inﬂammatorymarkers (Wang et al.,
2016b). LXR and SIRT1 expression levels were signiﬁcantly decreased in
HREC isolated from diabetic retinas compared to non-diabetic donor tis-
sue, conﬁrming that the SIRT1/LXR signaling pathway is downregulated
during diabetes (Fig. 1b). LXR isoforms,α andβ, were expressed at similar
levels in HREC (LXRα= 0.007 ± 0.002, LXRβ= 0.004 ± 0.001).Fig. 1. Diabetes leads to a signiﬁcant decrease in retinal LXR-SIRT signaling axis. (a) Retinas isol
levels of LXRαwhen compared to non-diabetic animals (n= 6). (b) HREC isolated from diabeti
donors (n = 3). TNFα, LXRα, LXRβ and SIRT1 expression levels were analyzed via qRT-PCR an
levels of natural LXR agonists oxysterols (n = 9). (d) Treatment with GW3965 an LXR agonist
when compared to diabetic untreated mice (middle panel) (n = 6). *p b 0.05.3.2. Retinas From T2D Rats Have Increased Levels of Cholesterol Esters and
Decreased Levels Oxysterols
To determine the effect of diabetes on retinal cholesterol metabo-
lism, T2D BBZDR rat model was used for lipid analysis. As shown in
Fig. 1C, oxysterol levels were decreased by 64% (p b 0.05) and total
cholesteryl ester abundance was increased in T2D retinas compared to
controls. Since diabetes induced a signiﬁcant decrease in LXR activators
oxysterols, these data suggest that LXR signaling and activation of
downstream targets will be impaired in diabetic tissue.
3.3. LXR Agonism Prevents the Development of Acellular Capillaries in db/db
Mouse Model
As all the components of SIRT1/LXR axis were downregulated in di-
abetic retinas and retinal cells, we next determined if pharmacological
activation of LXR could correct retinal vascular damage induced by dia-
betes. LXR activator GW3965 was administered to Leprdb/db diabetic
mice for 12 weeks, and diabetes-induced retinal vascular damage was
accessed. Diabetes induced an increase in the formation of acellular cap-
illaries in Leprdb/db 10-monthdiabeticmice as compared to non-diabetic
Leprdb/m controls, while GW3965 prevented diabetes-induced vascular
damage (Fig. 1d).
3.4. LXR Activation Restores CAC Cell Function in Diabetic Animals
Retinal vascular damage in diabetes is the combination of endotheli-
al cell injury and failed attempts at repair by dysfunctional CACs
(Chakravarthy et al., 2016). As systemic treatment with GW3965ated from diabetic mice (10months) have elevated TNFα expression levels, and decreased
c patients have decreased levels of LXRα, LXRβ and SIRT1when compared to non-diabetic
alysis. (c) Retinas from T2D rats have increased levels of cholesterol esters and decreased
, for 12 weeks prevented the formation of acellular capillaries in db/db mice (right panel)
Fig. 2. LXR activation restores CAC cell function in diabetic animals. CAC cell function was determined by measuring CAC migration. Diabetes (10 months) (white bars) impairs CAC
migration in response to SDF-1 and VEGF when compared to nondiabetic controls (dark grey bars). Treatment with GW3965 signiﬁcantly improves CAC migration in response to SDF-
1 and VEGF in diabetic mice (light grey bars) when compared to untreated diabetic mice (white bars) (n = 6). *p b 0.05.
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GW3965 on CAC migration. Diabetes induced a decrease in CAC migra-
tion in Leprdb/db 10-month diabetic mice as compared to non-diabetic
controls. GW3965 increased in CAC migration in response to SDF-1
(Fig. 2).3.5. LXR Activation Reduces Pro-inﬂammatory Cytokine Expression by
Macrophages
Inﬂammation has a well-established role in DR pathogenesis and
bone marrow-derived myeloid cells could contribute to the inﬂamma-
tory phenotype (Hu et al., 2013). We next determined if LXR activation
can affect macrophage function. Bone marrow derived macrophages
were stimulated using LPS and IFN-γ in the presence or absence of 10
μM of the LXR agonist, GW3965. LPS and IFN-γ stimulation induced a
strong inﬂammatory response as shown by IL-1β (Fig. 3a) and IL-6
(Fig. 3b) upregulation, while LXR activation inhibited this inﬂammatory
response.Fig. 3. LXR activation reduced proinﬂammatory expression stimulated by bone marrow-derive
100 ng/ml LPS and 40 ng/ml IFN-γ (c, d) 30 mM glucose, 10 nM insulin and 400 μΜ for 18 h in
expression (n = 3 per group). met = metabolic stimuli. *p b 0.05.To mimic the effect of diabetes, bone marrow derived macrophages
were challenged withmetabolic stimuli (30 mM glucose, 10 nM insulin
and 400 μMpalmitate) in the presence or absence of 10 μMLXR agonist,
GW3965 (Kratz et al., 2014). The metabolic stimuli, reduced ABCA1
mRNA expression (Fig. 3c), a target of the LXR pathway, and signiﬁcant-
ly increased IL-6 mRNA expression (Fig. 3d). LXR activation increased
ABCA-1 expression and at the same time downregulated the induction
of IL-6.
3.6. Pro-inﬂammatory Cytokines Signiﬁcantly Decrease Expression of LXRα
and RCT Genes in Bovine Retinal Endothelial Cells (BREC)
Retinal endothelial cells are exposed to cytokines produced by both
retinal cells and bone marrow derived myeloid cells. To mimic the pro-
inﬂammatory conditions found in the diabetic retina and their effects on
LXR and RCT genes, BREC were treated with 10 ng/ml TNFα for 24 h.
TNFα caused a signiﬁcant decrease in LXRα but not LXRβ levels
(Fig. 4a). Additionally, TNFα stimulation caused a signiﬁcant decrease
in the ATP-binding cassette transporters, ABCA1 and ABCG1.d macrophages. qRT-PCR was performed BM-derived macrophages stimulated with (a, b)
the absence or presence of 10 μΜ GW3965. (a) IL-1β, (b, d) IL-6 (c) ABCA1 mRNA relative
Fig. 4. TNFα causes a decrease in LXRα and reverse cholesterol transport genes in bovine retinal endothelial cells (BREC). BREC were treated with TNFα (10 ng/ml), SRT1720 (1 μM) or
DMHCA (1 μM) for 24 h. (a) Treatment with TNFα caused a signiﬁcant downregulation of LXRα, ABCA1, and ABCG1 (n=12). (b) SIRT1 siRNA signiﬁcantly decreases ABCA1mRNA levels.
BREC were treated with 100 nM control or SIRT1 siRNA for 48 h (n = 6). (c) LXR activators, GW3965 and DMHCA, effect on SREBP-1 mRNA levels. BREC were treated with either 10 μΜ
GW3965, 1 μΜDMHCA, or 0.1 μΜDMHCA for 24h (n=3). (d) LXR activation blocks TNFα-inducedABCA1 andABCG1 downregulation. ABCA1 andABCG1were signiﬁcantly decreased in
BREC treated with TNFα (n = 6). LXR activator, DMHCA inhibited TNFα-induced ABCA1, and ABCG1 downregulation (n = 6). (e) Western blot analysis of ABCA1 in BREC treated with
TNFα± DMHCA. β-actin was used as loading control (n = 3). Data analyzed via qRT-PCR. Cyclophilin A was used as a loading control. ***p b 0.001 **p b 0.01, *p b 0.05.
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SIRT1 has been shown to activate LXR via deacetylation. Subse-
quently, LXR activation promotes ABCA1 and ABCG1 expression
(Kalaany and Mangelsdorf, 2006). In order to address the involvement
of SIRT1 in increasing ABCA1 and ABCG1 in BRECs, loss of function stud-
ies were conducted using SIRT1-directed siRNA (Supplemental Table 2).
Administration of 100 nM SIRT1 siRNA caused a signiﬁcant decrease in
ABCA1 levels but not ABCG1 levels when compared to cells treated
with non-speciﬁc control siRNA (Fig. 4b). Inhibition of SIRT1 with
SIRT1-directed siRNA did not affect LXRα/β expression levels.3.8. LXR Activation via DMHCA Treatment Blocks TNFα-Induced ABCA1 and
ABCG1 Downregulation
Synthetic LXR ligands, such as GW3965 used in the initial experi-
ments, induce SREBP-1c, the master regulator of lipogenesis leading to
fatty liver disease (Joseph et al., 2002). To circumvent this problem, a
unique lipid LXR modulator N,N-dimethyl-3β-hydroxy-cholenamide
(DMHCA) has been developed. DMHCA activates LXRs while minimally
affecting SREBP-1c or activating fatty acid synthesis in the liver, kidney
or intestine (Quinet et al., 2004). In our studies, treatment of BRECswith
GW3965 (10 μM) and DMHCA (0.1 μM) causes a signiﬁcant increase in
ABCA1 and ABCG1 expression. This was accompanied by signiﬁcant in-
crease in SREBP-1c expression by GW3965 (10 μM), while DMHCA (0.1
μM)causedminimal SREBP-1c upregulation (Fig. 4c).Whenhigher dose
of DMHCA (1 μM)was used, it did induce SREBP-1c upregulation, how-
ever the effect on ABCA1 and ABCG1 upregulation was more robust
when compared to GW3965 (10 μM) (Fig. 4c). To achieve maximal ac-
tivation of downstream LXR targets such as ABCA1 and ABCG1,
DMHCA was used at the 1 μM concentration. Future animal studies
will be conducted usingDMHCA at 0.1 μMto avoid potential side effects,
such as lipogeneses, in vivo. AsDMHCA could be a promising pharmaco-
logical agonist of LXRs, we next addressed the effectiveness of DMHCAin retinal cells. BREC were treated with 1 μM DMHCA for 24 h in the
presence or absence of TNFα. Treatment with DMHCA alone caused a
signiﬁcant upregulation of both ABCA1 and ABCG1. Treatment with
DMHCA prevented TNFα-induced downregulation of both ABCA1 and
ABCG1 (Fig. 4d), suggesting that activation of LXR is sufﬁcient to restore
cholesterol efﬂux after TNFα stimulation in BREC. ABCA1 protein levels
are signiﬁcantly decreased in the presence of TNFα but LXR activation
via DMHCA prevents this TNFα-induced downregulation (Fig. 4e). In-
terestingly, treatment with SIRT1 activator, SRT1720, does not prevent
ABCA1 or ABCG1 downregulation in BREC (Supplemental Fig. 1).
3.9. Activation of the SIRT1/LXR Signaling Pathway Blocks Inﬂammation
Besides modulating cholesterol efﬂux transport pathways, LXR acti-
vation is also known to stabilize NFκB co-repressor complex preventing
pro-inﬂammatory gene upregulation (Joseph et al., 2003). To address
the effect of SIRT1/LXR modulation on inﬂammation, IL-1β and IL-6
were used as inﬂammation markers. BREC were treated with either
the LXR activator DMHCA (1 μΜ) or SIRT1 activator SRT1720 (1 μM)
for 24 h. As expected, stimulation with TNFα (10 ng/ml) caused a
marked increase in IL-1β and IL-6 expression levels. Treatment with ei-
ther DMHCA (Fig. 5a, c) or SRT170 (Fig. 10b, d) signiﬁcantly reduced
TNFα-induced IL-1β and IL-6 upregulation.
4. Discussion
As DR is a multi-faceted disease involving direct retinal cell damage
by diabetic milieu, as well as inﬁltration of pro-inﬂammatory bonemar-
row-derivedmyeloid cells, and loss of function of reparative CACs in di-
abetes, we examined SIRT1/LXR axis in these tissues.
Activation of the LXR signaling pathway has dual beneﬁcial conse-
quences. First, LXR signaling has been shown to directly cause down-
stream activation of the RCT pathway via ABCA1 and ABCG1
activation. These membrane-associated protein transporters are the
ﬁrst step in the RCT pathway and are major regulators of cellular
Fig. 5. LXR and SIRT1 activation blocks TNFα-induced IL-1β and IL-6 upregulation. BRECs were treated with TNFα (10 ng/ml), DMHCA (1 μΜ), SRT1720 (1 μM) and a combination of
DMHCA (1 μΜ) or SRT1720 plus TNFα (10 ng/ml). Data were analyzed using qRT-PCR (a, b, d, e) and ELISA (c, f). Cyclophilin A was used as a loading control for qRT-PCR. IL-1βmRNA
(a, b) and protein (c) as well as IL-6 mRNA (d, e) and protein (f) levels were signiﬁcantly increased in BRECs treated with TNFα for 24 h (n = 8). Administration of (a, c) DMHCA or
(b, e) SRT1720 for 24 h inhibited TNFα-induced IL-1β levels and IL-6 levels respectively (n = 6). ***p b 0.001 **p b 0.01, *p b 0.05.
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to lipid poor apolipoproteins (ApoA1 and ApoE) (Demina et al., 2016).
The RCT pathway is actively used by the retina to transport cholesterol
back to the liver in amulti-step process (Fliesler, 2015). Genetic manip-
ulation studies have demonstrated that downregulation of ABCA1 leads
to pathologic vessel thickening and hardening (Aiello et al., 2003). Loss
of ABCA1 and ABCG1 also leads to accumulation of inﬂammatory mac-
rophage foam cells in mice myocardium, lung, liver spleen and thymus
(Yvan-Charvet et al., 2007). Additionally, individuals with ABCA1muta-
tions are diagnosed with Tangier disease, a disease that is characterized
by a severe reduction inHDL. Activated LXR has also been shown to bind
to and stabilize NCoR Complex, thus inhibiting signaling through NFκB
response element on inﬂammatory gene promoters resulting in re-
duced inﬂammation (Huang et al., 2011).
There two LXR isoforms, LXRα and LXRβ, that are closely related
sharing 80% homology in their DNA and ligand binding domains (Zhao
and Dahlman-Wright, 2010). Relative expression levels of LXRα and
LXRβ vary among different tissues. In the retina, both isoforms are
expressed with LXRα localized to the nerve ﬁber layer and RPE while
LXRβ is expressed in all retinal layers and RPE as well (Dwyer et al.,
2011). Our previous study using STZ-induced T1Dmodel demonstrated
that enhanced LXR activity is protective against diabetes-induced reti-
nal vascular damage, whereas LXRα−/− and LXRα/β−/− caused retinal
vascular damage and development of acellular capillaries even in the
absence of diabetes (Hazra et al., 2012). This study further expands
these data demonstrating that LXR activation also prevented the devel-
opment of acellular capillaries in T2D Leprdb/db model.
Importantly, HRECs isolated from diabetic donors had decreased
levels of LXRα and LXRβ as compared to control tissue. To further ad-
dress the role of LXR in diabetes-induced retinal endothelial cell dam-
age, we used BREC. Inﬂammatory cytokines have a well-accepted role
in endothelial cell damage in DR, thus we used cytokine-stimulated
BREC as an in vitro model of DR (Joussen et al., 2004). BREC treated
with TNFα had reduced expression level of LXRα, that was accompa-
nied by the reduction in RCT genes ABCA1 and ABCG1, as well as upreg-
ulation of IL-1β and IL-6 expression levels. Treatment with the LXR
activating ligand, DMHCA, led to signiﬁcant upregulation of ABCA1
and ABCG1, and downregulation of IL-1β and IL-6 expression both in
the absence and presence of TNFα. These data are in agreement with
a dual role of LXR through both activation of RCT by binding to the
LXR response element onABCA1 andABCG1 genepromoters, and in sta-
bilizing the NCoR complex to inhibit signaling through NFκB responseelement on inﬂammatory gene promoters in retinal endothelial cells.
Although both LXRα and LXRβ isoforms are expressed in retinal endo-
thelial cells, therewas amore pronounced effect of diabetes and inﬂam-
mation regulated through LXRα rather than LXRβ expression.
In addition to direct effects of the diabetic metabolic milieu, activat-
edmacrophages can contribute to inﬂammatory conditions in the retina
(Chakravarthy et al., 2016; Hazra et al., 2013). Both LXRα and LXRβ iso-
forms are expressed inmacrophages. Activation of LXRs inmacrophages
suppresses the induction of inﬂammatory genes by LPS and leads to up-
regulation of RCT genes, ABCA1 and ABCG1, causing cholesterol efﬂux.
Our data conﬁrms that LXR activation using LXR agonist GW3965 in-
hibits LPS-induced cytokine production by macrophages. We further
demonstrate that metabolic stimuli (palmitate, insulin, glucose) lead
to reduced RCT genes (ABCA1) and increased cytokine production in
the macrophages. Treatment with this LXR ligand reversed both
ABCA1 inhibition and increase in IL-6 production in stimulated macro-
phages, strongly supporting a beneﬁcial role of LXR activation in meta-
bolically challenged macrophages in diabetes.
Lastly, CAC dysfunction leading to inadequate retinal vascular repair
is an important contributor to DR pathogenesis. We previously demon-
strated the importance of LXR signaling in CAC function using “loss of
function” studies where LXRα/β−/− animals had signiﬁcantly de-
creased CAC migration when compared to wild-type animals. The data
presented here show that activation of LXR prevents diabetes-induced
loss of CAC migration and function. Taken together, the results of this
study demonstrate that LXRs are downregulated in diabetes and activa-
tion of LXR signaling has the potential to restore normal cholesterolme-
tabolism as well as to have anti-inﬂammatory effects in retina and
retinal cells, as well as activated macrophages and CACs, thus affecting
all multiple aspects of DR pathogenesis.
It is important to note that although GW3965 activates LXR and pre-
vents acellular capillary formation in mice, this compound has been
shown to cause lipogenesis by activation of the SREBP-1c pathway lead-
ing to negative side (Quinet et al., 2004). Unlike GW3965, lipid LXR
modulator DMHCA has less effect on SREBP-1, while inducing a robust
activation of LXR leading to ABC upregulation (Fig. 4C). Additionally,
the Quinet et al., group demonstrated that when DMHCA is adminis-
tered in the presence of GW3965, DMHCA acts as a gene-selective func-
tional antagonist and partially blocks GW3965-induced increased in
SREBP-1c mRNA. Importantly, ABCA1 regulation is not affected and
the ligand retains agonist properties for ABCA1 (Quinet et al., 2004).
DMHCA also decreased atherosclerosis in the ApoE−/− mouse model
Fig. 6. Diabetes-induced decrease in SIRT1 and LXR levels results in an increase in hyperglycemia and dyslipidemia leading to progression of diabetic retinopathy (a). T2D-associated
decrease in Sirt1 levels results in increased levels of acetylated LXR, which is inactive. By increasing Sirt1 levels back to nondiabetic levels, deacetylation and thus activation of LXR is
facilitated. LXR activation then increases reverse cholesterol transport and represses the NFkB response element (NFkB RE) on inﬂammatory genes (b).
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(Kratzer et al., 2009). We tested DMHCA in BREC cell culture model in
this study. DMHCA was highly effective at activating LXR-dependent
RCT genes and at inhibiting expression of inﬂammatory genes in cyto-
kine-stimulated BREC.
Although the beneﬁcial effects of LXR signaling have been suggested
to play a key role in vascular diseases such as atherosclerosis and diabe-
tes, themechanism of action in which LXR activation inﬂuences inﬂam-
mation and cholesterol metabolism remains an active area of
investigation. LXR activity was recently shown to be controlled by acet-
ylation at a single conserved lysine, speciﬁcally by a well-known
deacetylase SIRT1 (Li et al., 2007). SIRT1 along with LXRα/β are highly
expressed in retinal tissue, macrophages and CACs. SIRT1 signaling has
been suggested to drive polarization of macrophages to non-inﬂamma-
tory states (Purushotham et al., 2009). Moreover, mouse SIRT1 knock-
down studies show signiﬁcant retinal abnormalities suggesting that
this enzyme plays a beneﬁcial role in retinal development and health
(Yuen et al., 2012; Kowluru et al., 2014). Recent studies suggest that
SIRT1 promotes insulin secretion, reduces glucose tolerance and de-
creases body weight in a LXR-dependent manner (Balestrieri et al.,
2013; Li et al., 2015; Zabolotny and Kim, 2007). Here, we show that cho-
lesterol metabolism, as examined via ABCA1/ABCG1 expression levels,
is signiﬁcantly affected when SIRT1 is inhibited. Interestingly, LXR
total levels are not affected via loss of SIRT1 suggesting that SIRT1
does not affect LXR expression levels but rather controls LXR activity.
Additionally, activation of SIRT1 signiﬁcantly reduces upregulation
pro-inﬂammatory genes in retinal endothelial cells (Fig. 5).
Taken together, our studies demonstrate that type 2 diabetes has a
detrimental effect on SIRT1-LXR signaling. Importantly, activation of
this signaling axis not only promotes cholesterol metabolism but is
also represses pro-inﬂammatory gene upregulation (Fig. 6). Future
studies are needed to investigate the mechanism of SIRT1 activation of
LXR resulting in stimulation of cholesterol metabolism pathways as
well as repression of pro-inﬂammatory genes. These mechanistic stud-
ies will determine the best approach in which to utilize the SIRT1/LXR
axis as a pharmacological target to treat DR.Funding Sources
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